Efficient modification of PAMAM G1 dendrimer surface with β-cyclodextrin units by CuAAC: impact on the water solubility and cytotoxicity

The toxicity of the poly(amidoamine) dendrimers (PAMAM) caused by the peripheral amino groups has been a limitation for their use as drug carriers in clinical applications. In this work, we completely modified the periphery of PAMAM dendrimer generation 1 (PAMAM G1) with β-cyclodextrin (β-CD) units...

Full description

Saved in:
Bibliographic Details
Published inRSC advances Vol. 1; no. 43; pp. 25557 - 25566
Main Authors Sorroza-Martínez, Kendra, González-Méndez, Israel, Martínez-Serrano, Ricardo D, Solano, José D, Ruiu, Andrea, Illescas, Javier, Zhu, Xiao Xia, Rivera, Ernesto
Format Journal Article
LanguageEnglish
Published England Royal Society of Chemistry 07.07.2020
The Royal Society of Chemistry
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The toxicity of the poly(amidoamine) dendrimers (PAMAM) caused by the peripheral amino groups has been a limitation for their use as drug carriers in clinical applications. In this work, we completely modified the periphery of PAMAM dendrimer generation 1 (PAMAM G1) with β-cyclodextrin (β-CD) units through the Cu( i )-catalyzed azide-alkyne cycloaddition (CuAAC) to obtain the PAMAM G1-β-CD dendrimer with high yield. The PAMAM G1-β-CD was characterized by 1 H- and 13 C-NMR and mass spectrometry studies. Moreover, the PAMAM G1-β-CD dendrimer showed remarkably higher water solubility than native β-CD. Finally, we studied the toxicity of PAMAM G1-β-CD dendrimer in four different cell lines, human breast cancer cells (MCF-7 and MDA-MB-231), human cervical adenocarcinoma cancer cells (HeLa) and pig kidney epithelial cells (LLC-PK1). The PAMAM G1-β-CD dendrimer did not present any cytotoxicity in cell lines tested which shows the potentiality of this new class of dendrimers. The toxicity of the poly(amidoamine) dendrimers (PAMAM) caused by the peripheral amino groups has been a limitation for their use as drug carriers in clinical applications.
Bibliography:10.1039/d0ra02574g
Electronic supplementary information (ESI) available. See DOI
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These people contributed equally to this work.
ISSN:2046-2069
2046-2069
DOI:10.1039/d0ra02574g